Drugs / GPC3 and/or TGFβ targeting CAR-T cells
GPC3 and/or TGFβ targeting CAR-T cells
also known as
GPC3/TGFβ-CART
Cell therapy targets GPC3 via depletion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03198546 | Jul 2017 → Aug 2029 expected | hepatocellular carcinoma, squamous cell lung carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GPC3 and/or TGFβ targeting CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03198546 ↗ |
| Known as | GPC3/TGFβ-CART | “The third/fourth generation of CAR-T cells that target GPC3 (GPC3-CART cell) and/or soluble TGFβ (GPC3/TGFβ-CART )have been constructed” NCT03198546 ↗ |
| Action | Deplete | “GPC3-CAR T cells were capable of effectively eliminating tumors in PDX model of HCC.” PMID 28123387 ↗ Jan 2017 |
| Modality | Cell therapy | “CAR T cells were adoptively transplanted into patient-derived xenograft (PDX) models of HCC.” PMID 28123387 ↗ Jan 2017 |
| Route | Other | “via artery or intra-tumor” NCT03198546 ↗ |
| Target | GPC3 | “CAR-T cells that target GPC3” NCT03198546 ↗ |